CLGN (CollPlant Biotechnologies) LT-Debt-to-Total-Asset: 0.20 (As of Mar. 2026)

What is CollPlant Biotechnologies LT-Debt-to-Total-Asset?

CollPlant Biotechnologies CLGN -0.03% 35 LT-Debt-to-Total-Asset is 0.20 as of Mar. 2026. GuruFocus rates CLGN with a GF Score™ of 35/100 and a GF Value™ of $0.29 (Modestly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CollPlant Biotechnologies's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.20.

CollPlant Biotechnologies's long-term debt to total assets ratio increased from Mar. 2025 (0.12) to Mar. 2026 (0.20). It may suggest that CollPlant Biotechnologies is progressively becoming more dependent on debt to grow their business.

CollPlant Biotechnologies (NAS:CLGN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CollPlant Biotechnologies LT-Debt-to-Total-Asset Related Terms

CollPlant Biotechnologies LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies LT-Debt-to-Total-Asset Chart

CollPlant Biotechnologies Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.07

0.12

0.19

CollPlant Biotechnologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.13	0.15	0.19	0.20

35GF Score

CollPlant Biotechnologies Ltd CLGN

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CollPlant Biotechnologies LT-Debt-to-Total-Asset Calculation

CollPlant Biotechnologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	2.032	/	10.785
	=	0.19

CollPlant Biotechnologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	1.855	/	9.183
	=	0.20

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.20 mean?

CollPlant Biotechnologies (CLGN) has a LT-Debt-to-Total-Asset of 0.20 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CollPlant Biotechnologies and its competitors.

Is CollPlant Biotechnologies' LT-Debt-to-Total-Asset too high?

CollPlant Biotechnologies' current LT-Debt-to-Total-Asset is 0.20. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does CollPlant Biotechnologies' LT-Debt-to-Total-Asset compare to CPMV and TCRT?

CollPlant Biotechnologies' LT-Debt-to-Total-Asset of 0.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current LT-Debt-to-Total-Asset is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CollPlant Biotechnologies stock overvalued right now?

Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.35 — trading 19.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.20. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current LT-Debt-to-Total-Asset is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of $0.35 is trading 19.9% above its estimated GF Value™ of $0.29. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for CLGN:

LT-Debt-to-Total-Asset: 0.20
GF Value™: $0.29 vs. price of $0.35 (19.9% above fair value)
GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CollPlant Biotechnologies Business Description

Industry Healthcare Biotechnology

Comparable Companies CPMV TCRT DRMA ENSC MBIO RNAZ ELAB ALZN PCSA CELZ VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CPT:Germany

Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

35GF Score

Get the complete analysis for CLGN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35

Price

$0.29

GF Value

View CLGN Analysis

See LT-Debt-to-Total-Asset data for all stocks →